← Back to Screener
Abeona Therapeutics Inc. Common Stock (ABEO)
Price$5.63
Value ScoreC
Growth ScoreF
Momentum ScoreB
Favorite Metrics
Price vs S&P 500 (26W)21.04%
Price vs S&P 500 (4W)1.47%
VGM Score43.64
Market Capitalization$329.43M
P/E Ratio (Annual)4.63x
All Metrics
Book Value / Share (Quarterly)$2.55
P/TBV (Annual)1.98x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)60.41%
Cash Flow / Share (Quarterly)$-1.50
Price vs S&P 500 (YTD)-1.26%
Gross Margin (TTM)73.55%
Net Profit Margin (TTM)490.36%
EPS (TTM)$0.87
10-Day Avg Trading Volume0.95M
EPS Excl Extra (TTM)$0.87
Revenue Growth (5Y)-10.26%
EPS (Annual)$1.08
ROI (Annual)39.71%
Gross Margin (Annual)73.68%
Net Profit Margin (5Y Avg)-1362.88%
Cash / Share (Quarterly)$2.96
P/E Basic Excl Extra (TTM)4.98x
P/E Normalized (Annual)4.63x
ROA (Last FY)32.42%
EBITD / Share (TTM)$1.07
ROE (5Y Avg)-155.78%
Operating Margin (TTM)575.17%
Cash Flow / Share (Annual)$-1.53
P/B Ratio2.27x
P/B Ratio (Quarterly)1.76x
Net Income / Employee (Annual)$315,000
EV / Revenue (TTM)19.68x
Net Interest Coverage (TTM)-127.06x
ROA (TTM)29.55%
EV / EBITDA (TTM)4.59x
EPS Incl Extra (Annual)$1.08
Current Ratio (Annual)6.93x
Quick Ratio (Quarterly)5.64x
3-Month Avg Trading Volume1.18M
52-Week Price Return-6.17%
P/E Incl Extra (TTM)4.98x
Revenue / Employee (TTM)$64,300
Tangible BV / Share (Quarterly)$1.51
P/S Ratio (Annual)56.60x
Asset Turnover (Annual)0.03x
52-Week High$7.54
Operating Margin (5Y Avg)-1525.44%
EPS Excl Extra (Annual)$1.08
CapEx CAGR (5Y)42.86%
Tangible BV CAGR (5Y)-30.62%
26-Week Price Return36.97%
Quick Ratio (Annual)6.70x
13-Week Price Return11.15%
Total Debt / Equity (Annual)0.13x
Current Ratio (Quarterly)5.89x
Enterprise Value$286.14M
Revenue / Share Growth (5Y)-49.56%
Asset Turnover (TTM)0.07x
Book Value / Share Growth (5Y)-36.03%
Revenue / Employee (Annual)$25,800
Inventory Turnover (Annual)1.30x
Pretax Margin (Annual)1224.79%
Cash / Share (Annual)$3.48
3-Month Return Std Dev47.04%
Gross Margin (5Y Avg)90.75%
Net Income / Employee (TTM)$292,600
ROE (Last FY)44.71%
Net Interest Coverage (Annual)-242.28x
EPS Basic Excl Extra (Annual)$1.08
P/FCF (TTM)189.33x
Receivables Turnover (TTM)1.59x
Total Debt / Equity (Quarterly)0.12x
EPS Incl Extra (TTM)$0.87
Receivables Turnover (Annual)0.94x
ROI (TTM)36.93%
P/S Ratio (TTM)22.66x
Pretax Margin (5Y Avg)-1362.53%
Revenue / Share (Annual)$0.09
Tangible BV / Share (Annual)$1.51
Forward P/E4.32x
Price vs S&P 500 (52W)-34.37%
P/E Ratio (TTM)4.98x
Year-to-Date Return9.68%
5-Day Price Return6.25%
EPS Normalized (Annual)$1.08
ROA (5Y Avg)-55.86%
Net Profit Margin (Annual)1223.08%
Month-to-Date Return5.86%
Cash Flow / Share (TTM)$-1.97
EBITD / Share (Annual)$0.99
Operating Margin (Annual)1081.07%
LT Debt / Equity (Annual)0.05x
ROI (5Y Avg)-148.07%
P/E Excl Extra (TTM)4.98x
LT Debt / Equity (Quarterly)0.03x
EPS Basic Excl Extra (TTM)$0.87
P/TBV (Quarterly)1.98x
P/B Ratio (Annual)1.79x
Inventory Turnover (TTM)1.30x
Pretax Margin (TTM)595.58%
Book Value / Share (Annual)$2.89
Price vs S&P 500 (13W)1.41%
Beta1.34x
Revenue / Share (TTM)$0.26
ROE (TTM)41.40%
52-Week Low$4.00
vGradeC
gGradeF
mGradeB
vgmGradeC
Show chart for
Earnings Surprise History
Q1 26-0.30est. -0.36
Analyst Recommendations
Feb 2026
Mar 2026
Apr 2026
May 2026
4.33
4.33
4.33
4.33
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
ABEOAbeona Therapeutics Inc. Common Stock | C | F | B | $5.63 |
| LLYEli Lilly & Co. | D | B | B | $1082.20 |
| JNJJohnson & Johnson | C | C | C | $223.51 |
| ABBVABBVIE INC. | D | C | C | $212.93 |
| MRKMerck & Co., Inc. | C | C | C | $115.17 |
| NVSNovartis AG | C | C | C | $145.68 |
| AZNAstraZeneca PLC | D | B | C | $179.71 |
| NVONovo-Nordisk A/S | B | B | C | $44.07 |
| PFEPfizer Inc. | B | C | C | $25.63 |
| ABTAbbott Laboratories | C | C | D | $87.78 |
| TEVATeva Pharmaceutical Industries Limited American Depositary Shares | C | C | C | $34.64 |
About
Abeona Therapeutics is a clinical-stage biopharmaceutical company developing gene therapies and plasma-based treatments for rare genetic diseases with significant unmet medical needs. The company's pipeline includes pz-cel, an autologous cell therapy in development for recessive dystrophic epidermolysis bullosa (RDEB), and adeno-associated virus (AAV)-based gene therapies for rare ophthalmic diseases. These programs target patient populations with limited treatment options and substantial commercial potential.